ReviewEuropean journal of haematology2013
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.
Review in European journal of haematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.Pathology oncology research : POR · 2016Trial
- Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.Journal of cancer research and clinical oncology · 2015Trial
- Management of skeletal-related events and fracture prevention in systemic mastocytosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Detection ofInternational journal of molecular sciences · 2024Review
- A case of high-risk AML in a patient with advanced systemic mastocytosis.Clinical case reports · 2023Article
- Mastocytosis in the Skin: Disease Heterogeneity among Children and Adults.Acta dermato-venereologica · 2023Article
- Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations.Journal of chemical theory and computation · 2022Article
- Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.Cancers · 2022Review
- Avapritinib for Systemic Mastocytosis.Expert review of hematology · 2021Article
- Successful treatment with avapritinib in patient with mucosal metastatic melanoma.Therapeutic advances in medical oncology · 2020Article
- Mastocytosis: from a Molecular Point of View.Clinical reviews in allergy & immunology · 2018Review
- Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Review
- Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.OncoTargets and therapy · 2016Review
- The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy.Leukemia · 2015Article
- The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Review
- Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.Immunology and allergy clinics of North America · 2014Review
- Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Haematologica · 2014Review
- Gene expression analysis in allergology: the prediction of Hymenoptera venom allergy severity and treatment efficacy.Clinical and translational allergy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apart from indolent systemic mastocytosis (SM), which is associated with a favorable prognosis, other subtypes of SM (SM with associated clonal hematologic non-mast cell lineage disease, aggressive SM, and mast cell leukemia - collectively referred to in this review as advanced SM) can be debilitating. The complexity of SM makes both the diagnosis and design of response criteria challenging for clinical studies. The tyrosine kinase KIT has been shown to play a crucial role in the pathogenesis of SM and has been a focal point in the development of targeted therapy. Mutations within various domains of the KIT receptor that lead to constitutive activation have been identified in patients, and those involving the activation loop of the KIT receptor are the mutations most frequently detected in patients with mastocytosis. Aberrant activation of the KIT receptor results in increased production of mast cells in extracutaneous organs that may lead to organ failure or early death. This review discusses the diagnosis and management of patients with advanced SM, including the relevance of KIT in this disease, potential therapies targeting this kinase, and criteria for measuring responses to these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.